Drugs / FGF-1
FGF-1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05493462 | Sep → Dec 2022 | Parkinson disease | Zhittya Genesis Medicine, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT00425178 | Sep 2005 → Sep 2006 | chronic ulcer of skin, diabetes mellitus | CardioVascular BioTherapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00117936 | Mar 2020 → Mar 2022 | arteriosclerosis disorder, coronary artery disorder, myocardial ischemia | CardioVascular BioTherapeutics, Inc. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00424866 Comparator | Dec 2020 → Dec 2021 | intermittent vascular claudication, peripheral arterial disease | CardioVascular BioTherapeutics, Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-10-06 | Celon Pharma SA | Results Celon Pharma na konferencji European Association for the Study of Diabetes celonpharma.com ↗
5 października naukowcy Celon Pharma pojawili się w Hamburgu i zaprezentowali wyniki badań dotyczące dwóch związków z naszego pipeline: analogu białka FGF-1 w normalizacji objawów cukrzycy typu 2 oraz skuteczności CPL207-280 w neuropatii cukrzycowej. |
| 2021-04-30 | CardioVascular BioTherapeutics, Inc. | Regulatory Venturis Therapeutics Inc. Announces Granting of US Patent for the Angiogenic Treatment of Ischemic Heart Disease, issued April 6, 2021, with 15 Patent Claims venturistherapeutics.com ↗
Dallas, TX - Venturis Therapeutics, Inc. (“VT” or the “Company”) today announced the issuance of U.S. Patent No. 10,966,610 entitled “Angiogenic Treatment of Ischemic Heart Disease”. |
| 2015-04-30 | Trefoil Therapeutics, Inc. | Results Trefoil Therapeutics To Present Data on Novel Class of Engineered FGF-1 Compounds at ARVO 2015 Meeting trefoiltherapeutics.com ↗
The study shows that eFGF-1s are potent stimulators of the proliferation of cultured rabbit and human corneal endothelial cells. |
All press releases naming this drug 6 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FGF-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00425178 ↗ |
| Known as | FGF1-141 | “Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose” NCT00117936 ↗ |
| Known as | Fibroblast Growth Factor-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00117936 ↗ |
| Known as | Human FGF-1 | “Human FGF-1” NCT05493462 ↗ |
| Known as | human fibroblast growth factor 1 | “human fibroblast growth factor 1 (FGF-1)” NCT05493462 ↗ |
| Known as | Human Recombinant Fibroblast Growth Factor-1 | “Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose” NCT00117936 ↗ |
| Modality | Protein / enzyme biologic | “a protein growth factor” NCT00117936 ↗ |
| Route | Intramuscular | “FGF-1 administered by intramuscular injection for the treatment of peripheral arterial disease with intermittent claudication.” NCT00424866 ↗ |